A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)

Trial Profile

A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Seladelpar (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors CymaBay Therapeutics; Vitaflo
  • Most Recent Events

    • 15 Aug 2017 Results from this trial have been published in Lancet Gastroenterology and Hepatology, according to a CymaBay Therapeutics media release.
    • 13 Apr 2017 According to a CymaBay Therapeutics media release, data from this study will be presented at the International Liver Congress 2017 sponsored by the European Association for the Study of Liver Diseases (EASL).
    • 20 Oct 2016 According to a CymaBay Therapeutics media release, results from this trial will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top